Ralinepag Cuts PAH Worsening Risk by 55% in Pivotal Trial, NDA Planned
Summary
United Therapeutics announced highly positive results from its pivotal Phase 3 ADVANCE OUTCOMES study for ralinepag, demonstrating a significant 55% reduction in the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH) compared to placebo. The trial met its primary endpoint with strong statistical significance (p<0.0001) and also showed improvements in key secondary endpoints like 6MWD and NT-proBNP. The safety profile was consistent with known prostacyclin-related events, with no new signals. These robust results are a major positive catalyst for United Therapeutics, significantly de-risking a key pipeline asset and paving the way for a New Drug Application (NDA) submission to the FDA by the second half of 2026. This development is expected to materially impact the company's future revenue potential and valuation.
At the time of this announcement, UTHR was trading at $495.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $266.98 to $537.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Unknown.